Microglial AGE-albumin is critical for neuronal death in Parkinson’s disease: A possible implication for theranostics

International Journal of Nanomedicine

Volumn 10, Issue Special Issue, 2016, Pages 281-292

  Bayarsaikhan, Enkhjargal ^a,b   Bayarsaikhan, Delger ^a   Lee, Jaesuk ^a   Son, Myeongjoo ^a   Oh, Seyeon ^a   Moon, Jeongsik ^a   Park, Hye Jeong ^a   Roshini, Arivazhagan ^a   Kim, Seung U ^c   Song, Byoung Joon ^d   Jo, Seung Mook ^e   Byun, Kyunghee ^a   Lee, Bonghee ^a  

^a Gachon University   (South Korea)

^b National Cancer Center of Mongolia   (Mongolia)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^e Eulji University   (South Korea)

Author keywords

AGE albumin; Microglia; Neuronal death; Parkinson s disease; Receptor of AGE; Theragnostic

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; ALPHA SYNUCLEIN; ASCORBIC ACID; BIOLOGICAL MARKER; CYTOCHALASIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAX; STRESS ACTIVATED PROTEIN KINASE; ADVANCED GLYCATION END PRODUCTS-BOVINE SERUM ALBUMIN; BOVINE SERUM ALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARBOHYDRATE SYNTHESIS; CELL ACTIVATION; CELL DEATH; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; THERANOSTIC NANOMEDICINE; UPREGULATION; ANIMAL; BRAIN; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOPRECIPITATION; METABOLISM; PATHOLOGY; TUNEL ASSAY; WESTERN BLOTTING;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN; CASE-CONTROL STUDIES; DOPAMINERGIC NEURONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; MICE; MICROGLIA; PARKINSON DISEASE; SERUM ALBUMIN, BOVINE; THERANOSTIC NANOMEDICINE;

EID: 85015078149     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S95077     Document Type: Article

References (37)

1. Poirier J, Kogan S, Gauthier S. Environment, genetics and idiopathic Parkinson’s disease. Can J Neurol Sci. 1991;18(1):70–76.
2. De Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community concerted action on the epidemiology of Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997; 62(1):10–15.
3. Calabrese VP. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;69(2): 223–224.
4. Przedborski S. Pathogenesis of nigral cell death in Parkinson’s disease. Parkinsonism Relat Disord. 2005;11 Suppl 1:S3–S7.
5. Albin RL, Dauer WT. Parkinson syndrome. Heterogeneity of etiology; heterogeneity of pathogenesis? Neurology. 2012;79(3):202–203.
6. Przedborski S. Inflammation and Parkinson’s disease pathogenesis. Mov Disord. 2010;25 Suppl 1:S55–S57.
7. Vives-Bauza C, Przedborski S. PINK1 points Parkin to mitochondria. Autophagy. 2010;6(5):674–675.
8. Lang AE, Obeso JA. Challenges in Parkinson’s disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 2004; 3(5):309–316.
9. Michel PP, Hirsch EC, Agid Y. Parkinson disease: mechanisms of cell death. Rev Neurol. 2002;158 Spec no 1:S24–S32.
10. Bognar C, Baldovic M, Benetin J, Kadasi L, Zatkova A. Analysis of Leucine-rich repeat kinase 2 (LRRK2) and Parkinson protein 2 (parkin, PARK2) genes mutations in Slovak Parkinson disease patients. Gen Physiol Biophys. 2013;32(1):55–66.
11. Kitada T, Mizuno Y. Molecular pathogenesis of familial Parkinson’s disease. Nihon Rinsho. 2000;58(10):2016–2021.
12. Hirsch EC, Hoglinger G, Rousselet E, et al. Animal models of Parkinson’s disease in rodents induced by toxins: an update. J Neural Transm Suppl. 2003;(65):89–100.
13. Thany SH, Reynier P, Lenaers G. Neurotoxicite des pesticides Quel impact sur les maladies neurodegeneratives? [Neurotoxicity of pesticides: its relationship with neurodegenerative diseases]. Med Sci. 2013; 29(3):273–278. French.
14. Binienda ZK, Sarkar S, Mohammed-Saeed L, et al. Chronic exposure to rotenone, a dopaminergic toxin, results in peripheral neuropathy associated with dopaminergic damage. Neurosci Lett. 2013;541:233–237.
15. Iancu R, Mohapel P, Brundin P, Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson’s disease in mice. Behav Brain Res. 2005;162(1):1–10.
16. Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson’s disease: a role in neurodegeneration? Ann Neurol. 1998;44(3 Suppl 1):S115–S120.
17. Luber-Narod J, Rogers J. Immune system associated antigens expressed by cells of the human central nervous system. Neurosci Lett. 1988; 94(1–2):17–22.
18. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):193–201.
19. Hirsch EC, Hunot S, Hartmann A. Neuroinflammatory processes in Parkinson’s disease. Parkinsonism Relat Disord. 2005;11 Suppl 1: S9–S15.
20. Ahn SM, Byun K, Cho K, et al. Human microglial cells synthesize albumin in brain. PLoS One. 2008;3(7):e2829.
21. Byun K, Bayarsaikhan E, Kim D, et al. Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer’s disease. PLoS One. 2012;7(5):e37917.
22. Byun K, Bayarsaikhan E, Kim D, et al. Activated microglial cells synthesize and secrete AGE-albumin. Anat Cell Biol. 2012;45(1):47–52.
23. Byun K, Bayarsaikhan D, Bayarsaikhan E, et al. Microglial AGE-albumin is critical in promoting alcohol-induced neurodegeneration in rats and humans. PLoS One. 2014;9(8):e104699.
24. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of proteins. J Biol Chem. 1992;267:4998–5004.
25. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2010; 106:842–853.
26. Scholz D, Poltl D, Genewsky A, et al. Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem. 2011;119(5):957–971.
27. Inden M, Kitamura Y, Abe M, Tamaki A, Takata K, Taniguchi T. Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol Pharm Bull. 2011; 34(1):92–96.
28. Munch G, Luth HJ, Wong A, et al. Crosslinking of alpha-synuclein by advanced glycation endproducts – an early pathophysiological step in Lewy body formation? J Chem Neuroanat. 2000;20(3–4):253–257.
29. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 1996;737(1–2):195–200.
30. Shaikh S, Nicholson LF. Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res. 2008;86(9):2071–2082.
31. Munch G, Westcott B, Menini T, Gugliucci A. Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids. 2012;42(4):1221–1236.
32. Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J. 2005;19(6):533–542.
33. Shaikh SB, Nicholson LF. Effects of chronic low dose rotenone treatment on human microglial cells. Mol Neurodegener. 2009;4:55.
34. Bucciarelli LG, Wendt T, Rong L, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59(7):1117–1128.
35. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108(7):949–955.
36. Walker DG, Lue LF. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer’s disease and other neurodegenerative diseases. J Neurosci Res. 2005;81(3):412–425.
37. Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie. 2011;93(4):645–658.